BioTuesdays

Tag - CBMG

Cellular Biomedicine Group

TBIG starts Cellular Biomedicine at buy; PT $19

TBIG launched coverage of Cellular Biomedicine Group (NASDAQ:CBMG) with a “buy” rating and $19 price target. The stock closed at $14.84 on Sept. 16. Cellular has been developing its cGMP grade cell therapy manufacturing...

Subscribe

Sign up to our weekly BioTuesdays newsletter.